Study on Sacituzumab Tirumotecan and Pembrolizumab Combination Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer with High PD-L1 Levels

Inclusion Criteria

• Diagnosed with non-small cell lung cancer (NSCLC) that is either squamous or non-squamous.
• Not suitable for treatments targeting EGFR, ALK, or ROS1 mutations.
• Tumor shows PD-L1 expression in 50% or more of cells.
• Good overall health with a performance status of 0 or 1.
• Expected to live at least 3 more months.
• If HIV-positive, must have well-controlled HIV on antiretroviral therapy.

Exclusion Criteria

• Diagnosed with small cell lung cancer or mixed tumors with small cell elements.
• Have significant nerve damage (Grade 2 or higher).
• Have severe eye conditions that affect healing.
• Have active inflammatory bowel disease or a history of it.
• Have uncontrolled heart or blood vessel disease within the last 6 months.
• Have received previous systemic cancer treatment for metastatic NSCLC.
• Have had prior treatment with certain immune therapies unless completed over a year ago for non-metastatic NSCLC.
• Have had recent cancer treatments or radiation therapy to the lung exceeding 30 Gy within 6 months.
• Have received a live vaccine within 30 days before starting the study.
• Have an immune deficiency or are on long-term steroid therapy.
• Have another progressing cancer or one treated in the last 3 years.
• Have active brain metastases or cancer in the brain lining.
• Have allergies to the study drugs or their components.
• Have an active autoimmune disease needing treatment in the last 2 years.
• Have a history of lung inflammation needing steroids or current lung inflammation.
• Have an active infection needing treatment.
• Have active Hepatitis B or C infections.
• Have HIV with a history of certain related diseases.
• Have had a tissue or organ transplant.
• Need treatment with certain strong medications affecting liver enzymes.